

# **Progressive Multifocal Leukoencephalopathy (PML) Drug Development Pipeline Study, H2 2018**

<https://marketpublishers.com/r/PC46AB4E9F5EN.html>

Date: August 2018

Pages: 35

Price: US\$ 1,200.00 (Single User License)

ID: PC46AB4E9F5EN

## **Abstracts**

Progressive Multifocal Leukoencephalopathy (PML) Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Progressive Multifocal Leukoencephalopathy (PML) pipeline products.

### **DISEASE OVERVIEW**

Progressive multifocal leukoencephalopathy (PML) is a rare but life-threatening condition, which is an infection of central nervous system. It is caused by human polyoma virus JC virus, which damages oligodendrocytes, resulting in nerve demyelination. Recently, patients undergoing immunotherapy are being reported to undergo Progressive multifocal leukoencephalopathy (PML).

Disease symptoms vary with the status of the disease ranging from gradual to worsening with time. Ataxia, paralysis, vision and speech problems and Coma are typical symptoms of PML.

Seven companies are actively developing new clinical compounds for administering patients with Progressive multifocal leukoencephalopathy. These companies include%li%Excision BioTherapeutics Inc, Forge Life Science LLC, Inhibikase Therapeutics Inc, Neurimmune Holding AG, Neuway Pharma GmbH, Pomona Ricerca SRL and Vir Biotechnology Inc.

### **REPORT DESCRIPTION**

The Progressive Multifocal Leukoencephalopathy (PML) pipeline guide presents complete overview of drugs currently being developed for Progressive Multifocal

Leukoencephalopathy (PML). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Progressive Multifocal Leukoencephalopathy (PML) pipeline candidate.

Research and Development progress along with latest news related to each of the Progressive Multifocal Leukoencephalopathy (PML) pipeline candidates is included.

Major companies participating in therapeutic development of Progressive Multifocal Leukoencephalopathy (PML) are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Progressive Multifocal Leukoencephalopathy (PML) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Progressive Multifocal Leukoencephalopathy (PML) clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Progressive Multifocal Leukoencephalopathy (PML) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

## **SCOPE OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) PIPELINE REPORT INCLUDES**

Panorama of Progressive Multifocal Leukoencephalopathy (PML) pipeline markets including statistics on therapeutic drugs and companies involved

Progressive Multifocal Leukoencephalopathy (PML) Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered

Progressive Multifocal Leukoencephalopathy (PML) pipeline candidates across various 'Mechanism of Actions' are also presented in the study

Overview of companies participating in Progressive Multifocal Leukoencephalopathy (PML) pipeline with short introduction to their businesses and pipeline projects

For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.

Research and Development progress and trial details, results wherever available, are also included in the pipeline study

The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Progressive Multifocal Leukoencephalopathy (PML) pipeline therapeutics

## **REASONS TO BUY**

Get clear understanding of the entire Progressive Multifocal Leukoencephalopathy (PML) pipeline, with details on active projects

Get in detail information of each product with updated information on each project along with key milestones

Know the list of companies participating in global Progressive Multifocal Leukoencephalopathy (PML) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

## Contents

### I. KEY FINDINGS

1. Companies Investing in Progressive Multifocal Leukoencephalopathy Pipeline include-

Number of Companies with Progressive Multifocal Leukoencephalopathy projects in pre-clinical Development-

Number of Companies with Progressive Multifocal Leukoencephalopathy projects in Clinical Development-

Progressive Multifocal Leukoencephalopathy Pipeline Companies based in Americas

Progressive Multifocal Leukoencephalopathy Pipeline Companies based in Europe

Progressive Multifocal Leukoencephalopathy Pipeline Companies based in Asia Pacific

Progressive Multifocal Leukoencephalopathy Pipeline Companies based in Rest of the World

2. Pipeline Candidates include-

Progressive Multifocal Leukoencephalopathy Pipeline Agents in pre-clinical/Discovery stage of Development

Progressive Multifocal Leukoencephalopathy Pipeline Agents in Clinical Development stage

Progressive Multifocal Leukoencephalopathy Pipeline Therapeutic Compounds received special status

Mechanism of Action of most pipeline Drugs-

Small molecules among the Progressive Multifocal Leukoencephalopathy Pipeline agents

### II. INSIGHTS INTO PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY PIPELINE

1. Disease Overview

Introduction to Progressive Multifocal Leukoencephalopathy

Symptoms and Causes of Progressive Multifocal Leukoencephalopathy

Treatment or Prevention Options for Progressive Multifocal Leukoencephalopathy

Other Details

2. Phase wise Pipeline Compounds

Progressive Multifocal Leukoencephalopathy Pipeline- Pre-Clinical/Discovery stage Drugs

Progressive Multifocal Leukoencephalopathy Pipeline- Phase 1 stage Drugs

- Progressive Multifocal Leukoencephalopathy Pipeline- Phase 2 stage Drugs
- Progressive Multifocal Leukoencephalopathy Pipeline- Phase 3 stage Drugs
- Progressive Multifocal Leukoencephalopathy Pipeline- Pre-Registration stage Drugs
- 3. Company wise Progressive Multifocal Leukoencephalopathy Pipeline Compounds
- 4. Progressive Multifocal Leukoencephalopathy Pipeline by Mechanism of Action

### **III. PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY PIPELINE COMPOUND DETAILS**

EBT103

sirtuin-targeted drugs Viral Infections

IkT-1427

NI-307

NWP007

PN-JC

Monoclonal Antibody for JCV linked PML

Drug Details

1. Snapshot

Name of the Therapeutic Agent

Originator

Developing Company

Co-Developer/License Partner

Orphan Drug/Fast Track/Designation

Development Phase

2. Drug Overview

3. Mechanism of Action

4. Current Status

5. Clinical Trial Details

### **IV. PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY PIPELINE COMPANY BRIEFS**

Excision BioTherapeutics Inc

Forge Life Science LLC

Inhibikase Therapeutics Inc

Neurimmune Holding AG

Neuway Pharma GmbH

Pomona Ricerca SRL

Vir Biotechnology Inc

## **V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY PIPELINE MARKET**

### **VI. APPENDIX**

1. Publisher's Expertise
2. Research Methodology
3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability

## I would like to order

Product name: Progressive Multifocal Leukoencephalopathy (PML) Drug Development Pipeline Study, H2 2018

Product link: <https://marketpublishers.com/r/PC46AB4E9F5EN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PC46AB4E9F5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

